Dr. Natasha Singh is Senior Consultant and Head of department of Nuclear Medicine and PET-CT at P D Hinduja National Hospital, Mumbai, India, with over 17 years of experience in the speciality of Nuclear Medicine & PET-CT. Her expertise across wide spectrum includes PET-CT and SPECT-CT imaging in Oncology and in Benign conditions, PET-CT in infections and inflammatory conditions, FDG-labeled Leukocyte PET-CT for infection, PET & SPECT with fused MRI in pediatric epilepsy, PSMA PET-CT scan and Lu-PSMA radionuclide targeted therapy for prostate cancer, SPECT in cardiology Myocardial Perfusion study, Myocardial viability PET study, Thyroid and Parathyroid imaging, Nephrology, Lymphoscintigraphy, Radioactive iodine therapy for hyperthyroidism, and others.
She is faculty as Post Graduate Nuclear Medicine Teacher in accordance with the National Board of Examinations India, for doctors undergoing training for post graduate specialization (DNB) in Nuclear Medicine. She has been honoured as the ‘Distinguished National Board of Examinations teacher in Nuclear Medicine’, and awarded the ‘Teacher’s Award’ by Association of National Board Accredited Institutions Maharashtra, Gujarat, Goa Region -2019. She has trained several medical doctors enrolled in the ‘DNB Nuclear Medicine & PET-CT Post graduate degree course’ at P D Hinduja National Hospital, Mumbai, India.
She has been instrumental in introducing some of the novel new services at P. D. Hinduja National Hospital, Mumbai. Amongst these are –
- ‘Radiolabelled leukocyte PET-CT scan for infection imaging’. P D Hinduja is the only hospital in Mumbai and western India region, and one of the very few hospitals in India providing this infection imaging procedure. This different new kind of technique of PET-CT scan is an important tool to assist clinicians in challenging cases of suspected infection, and aids towards better treatment management.
- Introduced and set up the ‘Radionuclide targeted Lutetium PSMA therapy’ for metastatic prostate cancer.
- Introduced in 2009, the Radiolabelled Peptide Receptor Therapy for Neuroendocrine tumors – The Indian Protocol for the first time in collaboration with Bhaba Atomic Research Centre Mumbai.
Dr. Natasha Singh completed her M.B.B.S from Government Medical College, Patiala, India in 1996. She initially briefly trained in other fields of medicine for an overview of diseases, with better understanding and utility of the field of diagnostics specially Imaging. Amongst these trainings included, clinical and non invasive cardiology at Chandigarh, as registrar in Chest Medicine & TB at Government Medical College Chandigarh, registrar in Gynaecology at ESI referral hospital, New Delhi. She completed her Post Graduate Degree DNB in Nuclear Medicine, Diplomate of National Board, New Delhi, in 2005. She qualified the Radiation Safety Officer Examination in 2006, conducted by Atomic Energy Regulatory Board (AERB), BARC, Mumbai, India.
She gained experience as senior registrar in Bio-Imaging PET-CT and SPECT-CT unit at Tata Memorial Hospital, Mumbai, India, 2006 – 2007. She underwent extensive training specialized towards PET-CT imaging and systems.
She trained at Royal Liverpool University Hospital, Liverpool, UK, with specialized training towards Radiolabelled Peptide Receptor Therapy for Neuroendocrine cancer.
She also trained in various aspects of radionuclide therapy special focus on Lu-177 PSMA for prostate cancer and Lu-177 Dotatate/Dotatoc for neuroendocrine tumor, and Ga68 PSMA PET-CT diagnostic imaging - at ‘University Klinikum Hospital’, Ulm, Germany.
She participated and trained with multidisciplinary team meetings including clinical-scan sessions in nephrourology, neuroblastoma, pediatric epilepsy, musculoskeletal conditions, endocrinology - at ‘Great Ormond Street Hospital for children’, London.
She trained in nuclear cardiology, protocols and quality control aspects of SPECT-CT & PET-CT, observer in Digital PET-CT imaging, CT dose reduction protocols involved during PET imaging - at ‘Emory University school of medicine’, Atlanta, USA.
She was an active participant in “The 5th international workshop on PET in lymphoma” 2014, Menton, France - where the workshop brought together haematologists and nuclear medicine physicians in discussion for advances in the field of lymphoma imaging and to set new international trials.
She was instrumental in formation of Indo-European Education Forum and conducted two Indo-European Nuclear Medicine post graduate training courses in 2010 and 2011: with participation of experienced teachers from Europe. Amongst other programmes, she also conducted An All India Post Graduate teaching programme for DNB (Nuclear Medicine & PET-CT) students from all post graduate institutes and DNB centres from India, at New Delhi, 2008 : with participation of international faculty from USA, UK, Australia.
Dr. Natasha Singh is a Consultant in Nuclear Medicine and PET-CT at P D Hinduja National Hospital & Medical Research Centre, Mumbai, with over 10 years of experience, and is a qualified Post Graduate Medical Teacher.
She has gained extensive experience in the speciality of Nuclear Medicine with expertise across wide spectrum of various Nuclear Medicine services including PET-CT imaging, PET-CT guided applications, Diagnostic Radionuclide imaging in Oncology and Benign conditions, Therapeutic radionuclide applications including thyroid disorders, neuroendocrine tumors, bone pain palliation, radioembolisation procedures for hepatocellular cancer and liver metastasis.
She specializes in Diagnostic Molecular PET-CT imaging, with extensive work since 2003 in various cancers including Non Hodgkins lymphoma, Hodgkins lymphoma, breast cancer, lung cancer, bone and soft tissue cancers, cancers of head and neck, cancers of gastrointestinal tract, and cartilaginous tumors, amongst others. Her expertise extends to PET-CT guided Radiation Therapy Planning in certain cancers. She also specializes in PET-CT imaging in benign conditions specifically Aortoarteritis / Takayasu disease, infections, fever of unknown origin.
She started the pre-therapy diagnostic somatostatin receptor scan imaging with isotope Lutetium under the able guidance of a renowned head of the department, which was subsequently studied at various nuclear medicine centres across India. After training in the radiolabelled peptide receptor therapy for Neuroendocrine cancer at “Royal Liverpool University Hospital”, Liverpool, UK, in 2009, she was instrumental in setting up this cancer therapy in the private sector as part of Hinduja Hospital activity.
Her expertise includes Nuclear Cardiology including FDG PET imaging for myocardial viability, Nuclear Neurology with special attention towards Epilepsy, Nuclear Nephrology, and various other general Nuclear Medicine Procedures.
She is a qualified post graduate Medical Teacher as per the Eligibility Qualifications criteria of Teachers, in accordance with the National Board of Examinations India for medical graduates undergoing training for post graduate specialization (DNB) in Nuclear Medicine. She is part of the faculty conducting Post Graduate training programme for Medical Graduates in the speciality of Nuclear Medicine recognized by the National Board. She has trained several Medical Doctors enrolled in the post graduate DNB degree course in Nuclear medicine at P D Hinduja National Hospital & Medical Research centre, Mumbai, India. She has also conducted training of nurses, technologists, and paramedical personnel.
She completed her Post Graduate Degree in the speciality of Nuclear Medicine, Diplomate of National Board, New Delhi, in 2005. She underwent her training at P D Hinduja National Hospital & Medical research centre, Mumbai, a premier multi-speciality hospital accredited for Post Graduate Medical Courses (DNB) under National Board of Examinations.\
She qualified the Radiation Safety Officer Examination in 2006, conducted by Atomic Energy Regulatory Board (AERB), Bhaba Atomic research Centre (BARC), Mumbai, India.
She gained experience as senior registrar in Bio-Imaging PET-CT and SPECT-CT unit at Tata Memorial Hospital, Mumbai, India, 2006 – 2007. She underwent extensive training specialized towards PET-CT imaging and systems.
She received training at Royal Liverpool University Hospital, Liverpool, UK, in June 2009, with specialized training towards Radiolabelled Peptide Receptor Therapy for Neuroendocrine cancer.
She completed her M.B.B.S from Government Medical College, Patiala, India in 1996. She trained in various fields of medicine for an overview of diseases and disorders, and hands on insight towards various treatments and management protocols for better vision and understanding of treating the patient, with better understanding and utility of the field of diagnostics specially Imaging.
She gained experience as Registrar & Incharge treadmill stress testing lab :1997–1999, at ‘Heart Institute & Research centre’, Chandigarh. She received training in clinical and non invasive cardiology including ECG treadmill stress test, Exercise and pharmacological stress echo, Colour doppler echocardiography.
She worked as Registrar and trained in the department of Chest Medicine & TB at ‘Government Medical College Chandigarh’ in 1998. She also worked as Registrar in the department of Gynaecology at ‘ESI hospital’, New delhi from 2000-2001.
Membership of Academic bodies :
- Member of the Society of Nuclear Medicine India (SNMI)
- Member of Association of Nuclear Medicine Physicians of India (ANMPI)
- Member of Nuclear Cardiology Society of India (NCSI)
- Member of National Academy of Medical Sciences (NAMS)
Thesis Guide for post graduate DNB nuclear medicine program & Projects :
- Utility of PSMA PET-CT in primary staging of prostate carcinoma in different risk categories based on ISUP grading.
- Evaluation of Treatment response and comparison of F18 FDG PET-CT based PERCIST and Hopkin’s Criteria in patients of Non-small cell lung cancer.
- To analyze concordance of Q.Clear and VPHD PET reconstruction algorithms with respect to Deauville’s score on treatment response 18F-FDG PET-CT in patients of Diffuse large B-cell Lymphoma.
- Corelation of PSMA PET-CT with gleasons score and serum PSA level in patients with primary and recurrent prostate carcinoma.
- Comparison of delta SUV max & Deauville’s criteria to predict the response to chemotherapy on interim FDG PET-CT scan in patients with NHL (DLBCL)
- Comparison of semi-quantitative parameters : change in SUV (^SUV max), change in metabolic tumor volume (^MTV), & change in total lesion glycolysis (^TLG) for response assessment on interim FDG PET-CT in patients with Hodgkins lymphoma.
- Comparison of F18-FDG PET-CT scan with CT scan in detection of metastasis, recurrence, and assessment of response to cytostatic therapy in patients with renal cell carcinoma.
- Evaluation of early response to chemotherapy in patients with non-small cell lung cancer by comparison of PET-CT based EORTC and PERCIST criteria and comparison within both criterias using SUV normalized also for body weight.
- Does 18F-FDG PET-CT help in correctly identifying the grade of cartilaginous tumours and thereby prevent the need for biopsy.
- Detection of cortical bone metastasis in prostate cancer with F-18 fluoride PET in cases of negative Tc-99m MDP bone scintigraphy.
- Role of 18F-FDG PET-CT in the management of recurrent carcinoma ovary – with special emphasis on patients with rising CA-125 levels.
- The role of 18F-FDG PET-CT in early treatment response evaluation of locally advanced breast cancer post Neo-adjuvant chemotherapy – A pilot study.
- Comparison of 18F-FDG PET-CT with contrast enhanced CT scan in the assessment of residual / recurrent disease in patients of head and neck squamous cell carcinoma post definitive treatment : A prospective observational study.
- Predictive value of FDG PET-CT based parameters in prognosis of patients with thoracic esophageal carcinoma during evaluation at staging.
- To evaluate prognostic significance of metabolic derived tumor volume (MTV) at staging FDG PET-CT scan and to compare with SUV based response evaluation on interim FDG PET-CT scan in patients with NHL (DLBCL)
- Evaluation of 18F-FDG PET-CT based parameters in prediction of histopathological response to neoadjuvant chemotherapy in patients with osteosarcoma.
- The role of FDG PET-CT imaging in staging, treatment, and prognosis of patients with head and neck cancer.
- To study the effect of Aromatase Inhibitors on Glucose Metabolism in cancer patients using FDG-PET Scan
- Comparison of Planar V/Q scan, CT-SPECT V/Q Scan with CT Pulmonary Angiography in evaluation of patients suspected with Pulmonary Embolism
- Does Thallium Scan Increase the Specificity of FDG PET-CT Scan in Malignant Tumors, Post Treatment Assessment of Malignant Tumors
- Co-relation of SUV derived from 18FDG PET-CT study with age, stage, grade, hormonal status, Ki-67, Her2 status in breast cancer patients.
- To compare the role of 18F-FDG PET and CT scan in the detection of pulmonary metastasis.
- Sentinel node imaging incorporating SPECT CT and gamma probe.
- National Project : Multi-Centric Study for the Development and Validation of an Artificial Intelligence Based Tool for the Characterization of Lung Nodules from Chest Computed Tomography Imaging and Clinical Features– Co PI (2021)
- International Project : A phase 2, double-blind, placebo-controlled, study in subjects with early parkinsons disease. (2020)
- Chapter on “PET SCAN IN LYMPHOMA” in the book ‘Haematology Today 2005’
- ‘Role of 18F-FDG PET-CECT in detection of early recurrence with peritoneal disease in a case of adrenocortical carcinoma’
- ‘Incidental Detection of Mandibular Metastasis in Renal Cell Carcinoma on 99mTc-MIBI Scan’. Clinical Nuclear Medicine; Jan 2022
- ‘Post Covid-19 unusual inflammatory syndromes detected on 18F-FDG PET-CT scan.’ Clin Nucl Med 2022
- ‘18F-FDG PET-CT evaluation of primary adrenal ewing’s sarcoma with venous thrombosis: An unusual presentation.’ World Journal of Nuclear Medicine 2022
- ‘Can 18F-FDG PET/CT alone or combined with radiology be used reliably to grade cartilage bone neoplasms for surgical decision making?’ Nuclear Medicine Communications 2021
- ‘An unusual case of bilateral ureteric metastasis on PSMA PET-CT scan in carcinoma prostate.’ Clin Nucl Med 2021;10.1097
- ‘Pazopanib‐induced asymptomatic necrotizing pancreatitis diagnosed on 18F‐FDG PET‐CT scan’. Indian J Nucl Med; Oct 2021
- ‘To determine the prognostic significance of 18-fluorodeoxyglucose positron emission tomography/computed tomography scan-derived parameters (total lesion glycolysis and metabolic tumor volume) in patients of diffuse large B-cell lymphoma with only nodal involvement.’Indian J Nucl Med 2020; 35:100-4
- ‘Occult tumor-induced osteomalacia causing lesion detected by FDG-PET/CT scan’.
World J Nucl Med 2020;19:147-8
- ‘To evaluate prognostic significance of metabolic-derived tumour volume at staging 18-flurodeoxyglucose PET-CT scan and to compare it with standardized uptake value-based response evaluation on interim 18-flurodeoxyglucose PET-CT scan in patients of non-Hodgkin's lymphoma (diffuse large B-cell lymphoma)’
Nuclear Medicine Communications 2020 Apr;41(4):395-405
- ‘Metabolic imaging as a novel strategy in evaluation of mycotic abdominal aortic aneurysm : A case report and brief clinical review’.
Indian J Nucl Med 2017; Oct-Dec; 32(4): 336-339
- ‘Epitheliod Angiosarcoma : 10 years post renal transplant’.
South Asian J Cancer 2017; Apr-June; 6(2): 58
- ‘Unusual asymptomatic FDG avid pheochromocytoma in a case of myxoid liposarcoma of the extremity on FDG PET-CT’.
World Journal of Nuclear Medicine 2017, vol 16, issue 3 : 237 - 239
- ‘IgG4 related disease simulating Paraneoplastic syndrome- Role of 18FDG PET/CT imaging’
Indian Journal of Radiology and Imaging 2017 April-June; vol 27, issue 2 : 249
- ‘Extranodal natural killer / T cell lymphoma with cardiac and abdominopelvic nodular deposits : Unique presentation on 18-fluorodeoxyglucose positron emission tomography computed tomography scan’.
Asian Journal of Oncology, vol 3, issue 1, January-June 2017
- ‘Potassium Chloride infusion as the cause of altered bio distribution of 18F-Fluorodeoxyglucose on whole body positron emission tomography-computed tomography scan’.
World Journal of Nuclear Medicine , vol 16, issue 1, January-March 2017
- ‘Incidental finding of sternal cleft on Tc99m-MDP bone scan appearing as a Necklace’. Indian J Nucl Med 2016; Oct-Dec; 31(4): 315–317
- ‘Unusual case of infantile fibrosarcoma evaluated on F-18 FDG PET-CT’
Indian J Nucl Med 2016; 31 : 201-3
- ‘Intramedullary osteosclerosis of right femur confirmed on triphasic bone
SPECT-CT in a patient with equivocal radiological features’.
Indian J Nucl Med 2016, vol 31, issue 1: page 39
- ‘Unusual visceral distribution of 99mTc methylene diphosphonate in a case of hypercalcemia of malignancy’. Indian J Nucl Med 2016; vol 31: issue 1, page 67-68
- Evaluate prognostic significance of 18FDG PET-CT scan derived metabolic tumour volume (MTV) at staging and comparison with SUV based response evaluation on interim PET-CT in patients with Non Hodgkin's Lymphoma (DLBCL).
J Nucl Med May 1, 2016 vol. 57 no. supplement 2 1605.
- ‘Rare case of primary inferior vena cava leiomyosarcoma on F-18 fluorodeoxyglucose positron emission tomography-computed tomography scan : Differentiation from non tumor thrombus in a background of procoagulant state’.
Indian J Nucl Med 2014; vol 29, issue 4: 246-248
- ‘Lutetium Dotatate whole body scans – A novel approach for evaluation of
neuroendocrine tumors.’ Indian J Nucl Med 2011 Jul-Sep; 26(3):135-138
- ‘Sudden mono-ocular blindness with recurrent transient diplopia and ptosis
in a middle-aged woman’. BMJ Case Reports 2011; doi:10.1136/bcr.10.2010.3414
- ‘Percutaneous endoscopic gastrostomy site metastasis in head and neck
cancer : use of FDG PET-CT’. Diagn Interv Radiol 2008; 14: 88-93
- ‘Role of radionuclide scintigraphy in the detection of parathyroid adenoma’
Indian Journal of Cancer 2007; 44: 12-16
PET Scan., SPECT Scan